vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

About this update from Vtv Therapeutics Inc.

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of  cadisegliatin , a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv Therapeutics” Format: Fireside Chat Moderator: Emily Bodnar, Director, H.C. Wainwright vTv Therapeutics Speakers: Date: Thursday, June 12, 2025 Time: 10:00 AM ET Webcast Link: Register  here The webcast of the event will be accessible from News & Events page of the vTv website. About   vTv   Therapeutics vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by  cadisegliatin , currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at  vtvtherapeutics.com  or follow the company on  LinkedIn  or  X . Investor Contact John Fraunces LifeSci Advisors, LLC 917-355-2395 [email protected] Media Contact Caren Begun TellMed Strategies 201-396-8551 [email protected]

View stock analysis, news, and events for Vtv Therapeutics Inc.